Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the pharmacokinetic (PK) of selexipag and ACT-333679 following single oral administration of the matrix tablet and the encapsulated pellets of selexipag, each with 3 different release profiles, as compared to selexipag immediate release (IR) tablets in healthy male participants.
Interventions
DRUGSelexipag matrix tablet
Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
DRUGSelexipag encapsulated pellets
Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
DRUGSelexipag Immediate-release (IR) tablet
Participants will receive Selexipag immediate-release tablet orally under fasted condition.
Sponsors
Actelion
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening * Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participants may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator * Must sign an informed consent form (ICF) indicating they understand the purpose of, and procedures required for, the study and is willing to participate in the study * Body mass index (BMI; weight (kilogram \[kg\]/height\^2 \[meter {m}\]\^2) between 18.0 and 28.0 kilogram per square centimeter (kg/m\^2) (inclusive), and body weight not less than 50.0 kg at screening * Blood pressure (after the participant is supine for 5 minutes) between 90 and 145 millimeters of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic at screening. If blood pressure is out of range, up to 2 repeated assessments within the screening period are permitted, last assessment being conclusive
Exclusion criteria
* Clinically significant abnormal values for hematology, biochemistry, or urinalysis at screening and on Day -1 of Treatment Period 1 as deemed appropriate by the investigator * Known allergies, hypersensitivity, or intolerance to selexipag or its excipients * Any contraindication included in the Summary of Product Characteristics (SmPC) of selexipag * History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study treatments (appendectomy and herniotomy allowed, cholecystectomy not allowed) * Previous history of stroke, fainting, collapse, syncope, orthostatic hypotension, vasovagal reactions, head injury
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Analyte Concentration (Cmax) of Selexipag and ACT-333679 | Predose and 0 to 72 hours postdose | The Cmax is the maximum observed analyte concentration. |
| Area Under Analyte Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of Selexipag and ACT-333679 | Predose and 0 to 72 hours postdose | AUC (0-last) defined as the area under the analyte concentration-time curve from time zero to time of the last measurable (non-BQL) analyte concentration, calculated by linear-linear trapezoidal summation. |
| Plasma analyte concentration 24 hours (C24) Post Dose of Selexipag and ACT-333679 | Predose and 0 to 72 hours postdose | C24 defined as plasma analyte concentration at 24 hours postdose. |
| Area Under the Analyte Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) | Predose and 0 to 72 hours postdose | AUC (0-infinity) is defined the area under the analyte concentration-time curve from time zero to infinity time, calculated as the sum of AUC (0-last) and C(last)/lambda(z); wherein AUC (0-last) is area under the plasma concentration-time curve from time zero to last measurable concentration, C(last) is the last observed measurable concentration, and lambda(z) is apparent terminal elimination rate constant. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability | Up to 50 Days | An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment and can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. |
Countries
Belgium
Outcome results
None listed